Vaxcyte SVP uses 569 shares to cover RSU taxes

Vaxcyte’s SVP, Finance & CAO reported two routine share withholdings to satisfy tax obligations arising from RSU vesting.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, SVP, Finance & CAO, had two Form 4 transactions consisting of shares of common stock surrendered to cover tax withholding on vested restricted stock units. On August 31 and September 2, 2026, a total of 569 shares were withheld for this purpose.

Insider Trade Summary

Tax Withholding: 569 shares

Tax Withholding 2 txns

Insider Cowan Elvia

Role SVP, Finance & CAO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	326	$61.58	$20K
Tax Withholding	Common Stock F1, F2	243	$60.74	$15K

Holdings After Transaction: Common Stock — 29,187 shares (Direct)

Footnotes (2)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
2. F2. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.

Key Figures

Shares surrendered September 2, 2026: 326 shares Reference price September 2, 2026: $61.58 per share Shares surrendered August 31, 2026: 243 shares +3 more

6 metrics

Shares surrendered September 2, 2026 326 shares Common stock surrendered to cover tax withholding upon RSU vesting

Reference price September 2, 2026 $61.58 per share Value used for shares surrendered to cover tax obligations

Shares surrendered August 31, 2026 243 shares Common stock surrendered to cover tax withholding upon RSU vesting

Reference price August 31, 2026 $60.74 per share Value used for shares surrendered to cover tax obligations

Total shares surrendered for tax withholding 569 shares Sum of both code F transactions reported in this Form 4

ESPP shares included in holdings 781 shares Shares acquired under the Employee Stock Purchase Plan on May 15, 2026

Key Terms

Restricted Stock Units, Employee Stock Purchase Plan, tax withholding obligations

3 terms

Restricted Stock Units financial

"tax withholding obligations realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Purchase Plan financial

"Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

tax withholding obligations financial

"shares surrendered to the Issuer to cover applicable tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Vaxcyte (PCVX) executive Elvia Cowan report on this Form 4?

Elvia Cowan reported two dispositions of Vaxcyte common stock, totaling 569 shares, on August 31 and September 2, 2026. In both cases, shares were surrendered to Vaxcyte to cover tax withholding obligations upon vesting of restricted stock units.

Were the PCVX transactions by Elvia Cowan open-market sales or purchases?

No. Both transactions are coded as “F”, representing shares delivered or withheld to pay tax liability upon RSU vesting. They do not reflect open-market sales or purchases of Vaxcyte common stock.

How many Vaxcyte (PCVX) shares were withheld in each transaction?

On September 2, 2026, 326 shares of Vaxcyte common stock were surrendered at a reference price of $61.58 per share. On August 31, 2026, 243 shares were surrendered at a reference price of $60.74 per share.

What does the Form 4 disclose about Elvia Cowan’s ESPP activity in PCVX?

A footnote states that Cowan’s holdings include 781 shares acquired under Vaxcyte’s Employee Stock Purchase Plan on May 15, 2026. This contextual information relates to overall share ownership, not to the specific tax-withholding transactions.

Was a Rule 10b5-1 trading plan involved in these Vaxcyte (PCVX) transactions?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote indicating that a trading plan was used. The reported transactions are tied to tax withholding on RSU vesting rather than discretionary trading.

Do these PCVX Form 4 transactions show Elvia Cowan’s remaining share ownership?

No. The rows for these transactions show no post-transaction share totals, so remaining holdings are not specified here. The footnote only notes that holdings include 781 ESPP shares acquired on May 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:55 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		F		243(1)	D	$60.74	29,513(2)	D
Common Stock	09/02/2026		F		326(1)	D	$61.58	29,187	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

2. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)